EARLY IFNB-1a and Simvastatin Combination Therapy in Clinically Isolated Syndrome Suggestive of Multiple Sclerosis
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00146068 |
Recruitment Status :
Completed
First Posted : September 5, 2005
Last Update Posted : March 5, 2008
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Multiple Sclerosis | Drug: Avonex/Zocor | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Enrollment : | 30 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double |
Primary Purpose: | Treatment |
Official Title: | Phase IV Double-Blind Randomized Study to Evaluate Safety and Efficacy of Interferon Beta-1a (Avonex) Plus Simvastatin (Zocor) Combination Therapy in Clinically Isolated Syndrome Suggestive of Multiple Sclerosis Over a One Year Period |
Study Start Date : | September 2004 |
Actual Primary Completion Date : | December 2007 |
Actual Study Completion Date : | December 2007 |

- The primary objective of this study is to determine whether combination therapy with IFNb-1a plus simvastatin, when compared to IFNb-1a plus placebo decreases or delays additional clinical or MRI activity.
- We will use the following outcome measures:
- Relapse rates, Time to first relapse,Number of new T2 lesions, Number of new Gd-enhancing lesions

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 60 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Subject has a diagnosis of CIS suggestive of MS involving optic nerve (unilateral optic neuritis), spinal cord (incomplete transverse myelitis), brain stem or cerebellum syndrome confirmed by ophthalmologic or neurological examinations. (Onset of CIS symptoms must occur within twelve months of randomization).
- At baseline, subject will be between the ages of 18 and 60, inclusive.
- Subject has a baseline EDSS score between 0.0 and 5.5, inclusive.
- MRI findings on the brain scan should reveal at least three out the four following findings: one Gd-enhancing lesion or nine T2 hyperintense lesions; or at least one infratentorial lesion; or at least one juxtacortical lesion and or at least three periventricular lesions.
- Subject has signed informed consent and HIPAA forms.
Exclusion Criteria:
- Subject has a diagnosis of CD RRMS according to Poser criteria, definitive MS according McDonald criteria, secondary progressive, or primary progressive MS.
- Subject has been treated with statins in the previous three months. Subject has history of severe side effects related to statin therapy.
- Subject has had a clinically significant infectious illness (e.g., cellulitis, abscess, pneumonia, septicemia) within 30 days prior to randomization.
- Subject has a history of, or abnormal laboratory results indicative of, any significant cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, gastrointestinal, dermatologic, psychiatric, renal, and/or other major disease.
- Subject has a history of severe allergic or anaphylactic reactions or known drug hypersensitivity.
-
Subject has an abnormal screening blood test, performed at the screening visit, exceeding any of the limits defined below:
- alanine transaminase (ALT) or aspartate transaminase (AST) > 1.5 times the upper limit of normal (1.5x ULN)
- total white blood cell count < 2,300/mm^3
- CPK level > 2 x ULN on two consecutive occasions tested at least one week apart.
- Platelets less than 150,00/mm3
- Creatinine > 1.5mg/dl.
- prothrombin time (PT) > ULN
- Subject has history of treatment with either interferon-beta 1a or 1b, or glatiramer acetate.
-
Subject has had any prior treatment with any of the following medications:
- total lymphoid irradiation
- intravenous immunoglobulins IVIg, or plasma exchange
- natalizumab or any other therapeutic monoclonal antibody
-
Subject has had treatment with any of the following medications within 1 year prior to randomization:
- mitoxantrone
- cyclophosphamide
-
Subject has had treatment with any of the following medications:
- cyclosporine
- azathioprine
- methotrexate
- glatiramer acetate
- interferon beta-1b or INF beta-1a
- intravenous immunoglobulin (IVIG)
- plasmapheresis or cytapheresis
-
Subject has had treatment with any of the following medications within 50 days prior to randomization:
- intravenous corticosteroid treatment
- oral corticosteroid treatment
- Subject has a history of alcohol abuse within 2 years prior to randomization.
- Subject is a female who is not postmenopausal for at least one year, surgically sterile, or willing to practice effective contraception (as defined by the investigator) during the study. The rhythm method is not to be used as the sole method of contraception.
- Subject is a nursing mother, pregnant woman, or planning to become pregnant while on study.
- Subject has had participation in any other investigational study within 6 months prior to randomization.
- Subject is unwilling or is unable to comply with the requirements of this protocol including the presence of any condition (physical, mental, or social) that is likely to affect the subject's ability to comply with the study protocol.
- Subject is determined unsuitable for enrollment into this study for any other reason in the opinion of the Investigator and/or the Sponsor.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00146068
United States, North Carolina | |
University of North Carolina-Chapel Hill MS clinic within the Neuroscience Hospital | |
Chapel Hill, North Carolina, United States, 27599 |
Principal Investigator: | Silva Markovic-Plese | University of North Carolina, Chapel Hill |
Responsible Party: | Silva Markovic-Plese, MD/Principal Investigator, UNC-Chapel Hill |
ClinicalTrials.gov Identifier: | NCT00146068 |
Other Study ID Numbers: |
04-NEUR-387 |
First Posted: | September 5, 2005 Key Record Dates |
Last Update Posted: | March 5, 2008 |
Last Verified: | February 2008 |
Clinically Isolated Syndrome |
Multiple Sclerosis Sclerosis Pathologic Processes Demyelinating Autoimmune Diseases, CNS Autoimmune Diseases of the Nervous System Nervous System Diseases Demyelinating Diseases Autoimmune Diseases |
Immune System Diseases Interferon beta-1a Adjuvants, Immunologic Immunologic Factors Physiological Effects of Drugs Antineoplastic Agents Antiviral Agents Anti-Infective Agents |